Table 2.
“In vitro” effects of the glibenclamide, repaglinide, and diazoxide on flexor digitorum brevis muscle FDB muscle fiber viability in mice
| Time of Incubation (h) | ||||
|---|---|---|---|---|
| Treatment | Parameters | 1 | 24 | 48 |
| Controls | Diam. (μm) | 87.2 ± 2.7 (Nf = 35) | 83.7 ± 2.5 (Nf = 31) | 85.2 ± 2.5 (Nf = 28) |
| Mort. (%) | 1 ± 0.11 (Npl = 5) | 36 ± 8 (Npl = 5) | 68 ± 10 (Npl = 5) | |
| Glibenclamide (10−5 mol/L) | Diam. (μm) | 84 ± 3 (Nf = 28) | 72 ± 3.31 (Nf = 28) | 69 ± 6.11 (Nf = 22) |
| Mort. (%) | 8 ± 0.9 (Npl = 5) | 55 ± 81 (Npl = 5) | 98 ± 91 (Npl = 5) | |
| Repaglinide (10−5 mol/L) | Diam. (μm) | 83.8 ± 2.4 (Nf = 25) | 76.5 ± 2.41 (Nf = 28) | 70.1 ± 4.11 (Nf = 19) |
| Mort. (%) | 7.3 ± 3 (Npl = 5) | 52 ± 81 (Npl = 5) | 99 ± 61 (Npl = 5) | |
| Diazoxide (250 × 10−6 mol/L) | Diam. (μm) | 83 ± 6 (Nf = 15) | 82 ± 7.2 (Nf = 24) | 80.7 ± 3 (Nf= 28) |
| Mort. (%) | 1 ± 0.3 (Npl = 5) | 28 ± 7 (Npl = 5) | 58 ± 8 (Npl = 5) | |
| Glibenclamide (10−5 mol/L) + Diazoxide (250 × 10−6 mol/L) | Diam. (μm) | 81 ± 4 (Nf = 20) | 79 ± 3.1 (Nf = 23) | 85.7 ± 32 (Nf = 28) |
| Mort. (%) | 1.4 ± 0.42 (Npl = 5) | 38 ± 92 (Npl = 5) | 59 ± 82 (Npl = 5) | |
| Repaglinide (10−5 mol/L) + Diazoxide (250 × 10−6 mol/L) | Diam. (μm) | 82 ± 5.1 (Nf = 21) | 83 ± 4.1 (Nf = 25) | 85.9 ± 5.12 (Nf = 26) |
| Mort. (%) | 1.5 ± 0.62 (Npl = 5) | 40 ± 82 (Npl = 5) | 58 ± 102 (Npl = 5) | |
| Staurosporine (2 × 10−6 mol/L) | Diam. (μm) | 78.6 ± 4.4 (Nf = 29) | 66.5 ± 8.41 (Nf = 29) | 54.5 ± 9.41 (Nf = 29) |
| Mort. (%) | 16.3 ± 6 (Npl = 5) | 78 ± 91 (Npl = 5) | 96.2 ± 111 (Npl = 5) | |
The data are the mean ± SE of the diameter, Diam.; mortality, Mort. Treatment indicates the treatment in the presence of drugs or in the absence of drugs, controls. Nf, number of fibers; Npl, number of analyzed plates. The % of fibers mortality were fibers showing more than 40% change in the morphological parameters (length and diameters, blebs) and fails contractile response to ATP (1 mmol/L) or KCl (15 mmol/L).
Data significantly different between treatments evaluated by the two ways analysis of variance (P < 0.05).
Data significantly different between treatments (repaglinide-diazoxide and glibenclamide-diazoxide data vs. repaglinide and glibenclamide data) evaluated by the two ways analysis of variance (P < 0.05).